Oragenics, Inc. announced that Effective December 15, 2022, Ms. Kimberly Murphy, the company’s President and Chief Executive Officer, was appointed Interim Chief Financial Officer, Secretary and Treasurer of the company to serve while the Company conducts its search process to identity and appoint a new Chief Financial Officer. In addition, Mr. Sullivan has agreed to remain available to the Company as a consultant for a limited amount of time commencing December 15, 2022 through January 31, 2023 to continue to assist the Company with transition matters. The company previously reported Michael Sullivan’s resignation as Chief Financial Officer, Secretary and Treasurer of the Company, to be effective December 14, 2022, and the Company’s commencement of a search for his replacement.